Biotechnology companies are capitalizing on a growing federal effort to fund dementia research to develop new medications for Alzheimer’s disease, filling a gap in venture funding compared with investments to fight other diseases. Startups such as Alzheon Inc. and Cognition Therapeutics Inc. recently won grants from the National Institute on Aging, part of the National Institutes of Health, to finance clinical trials of medicines for Alzheimer’s, the most common cause of dementia. Current medicines treat Alzheimer’s symptoms,...

Source: Wall Street Journal August 20, 2020 10:07 UTC